tunlametinib + fruquintinib

This is a combination of **tunlametinib**, a selective MEK inhibitor, and **fruquintinib**, a highly selective vascular endothelial growth factor receptor (VEGFR) 1/2/3 inhibitor. Both are small molecule oral drugs. - **Tunlametinib** inhibits the MEK1/2 kinases in the MAPK pathway, frequently dysregulated in cancer, leading to inhibition of tumor cell proliferation. - **Fruquintinib** inhibits angiogenesis by blocking VEGFR1, VEGFR2, and VEGFR3, disrupting tumor blood supply and exerting antitumor effects. This combination is being clinically investigated for use in certain cancers, notably metastatic colorectal cancer and potentially other solid tumors, based on the rationale that dual inhibition of tumor growth pathways and angiogenesis may yield synergistic antitumor activity[1].

Other names

HMPL-013 (fruquintinib)ELUNATE (fruquintinib, China)tunlametinib (no brand/trade name identified)